Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Chronic Spontaneous Urticaria
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Efficacy and Safety of Subcutaneous Spesolimab for the Prevention of Generalised Pustular Psoriasis Flares (Effisayil 2): an International, Multicentre, Randomised, Placebo-Controlled Trial : Episode 2

Opinion

Video

October 29, 2024

Study Objectives and Key Inclusion Criteria for GPP Patients

Delve into the complexities of generalized pustular psoriasis (GPP), a rare and life-threatening skin condition, and explore how the monoclonal antibody spesolimab is being investigated to prevent severe, unpredictable flares.

EP: 1.Revolutionizing GPP Management: The Efficacy and Safety of Spesolimab in Preventing Life-Threatening Flares

Now Viewing

EP: 2.Study Objectives and Key Inclusion Criteria for GPP Patients

EP: 3.Spesolimab Dosing Regimens

EP: 4.Primary and Secondary Endpoints

EP: 5.Demographics and Baseline Characteristics Across Spesolimab Dose Groups

EP: 6.Spesolimab Efficacy Data

EP: 7.Fighting the Flare of GPP: Expert Insights on Spesolimab

EP: 8.Spesolimab Safety Data

EP: 9.Final Thoughts: The Spesolimab and GPP Flare Reduction

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!